Sarepta (SRPT) Bullish View Reiterated at Needham & Company on Expanded European DMD Pipeline

October 6, 2016 7:54 AM EDT
Get Alerts SRPT Hot Sheet
Price: $31.02 -1.24%

Rating Summary:
    17 Buy, 10 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 18 | Down: 17 | New: 10
Trade SRPT Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Needham & Company analyst Chad Messer reiterated a Buy rating and $81 price target on Sarepta Therapeutic (NASDAQ: SRPT) as the company expands its European DMD pipeline with the ezutromid deal.

Messer commented, "Sarepta is acquiring EU rights to Duchenne's muscular dystrophy (DMD) treatment ezutromid from Summit Therapeutics for $40M upfront. While we do not forecast ezutromid approval until at least 2019, the deal gives SRPT another shot on goal and we believe helps establish it as a leader in DMD therapy. Perhaps as important, we expect the collaboration to accelerate development of combination therapies which we expect will become the standard of care in DMD in the future. Notably, Sarepta also recently signed a collaboration agreement with Catabasis to study their NF-kB targeted DMD therapy in combination with Exondys 51. We maintain our Buy rating and $81 price target. Separately, we introduce a new model for US Exondys launch."

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $62.35 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Related Entities

Needham & Company

Add Your Comment